Organon (OGN) Depreciation and Depletion (2020 - 2026)
Organon (OGN) posted quarterly Depreciation and Depletion of $39.0 million for Q1 2026, up 14.71% year-over-year from $34.0 million in Q1 2025, and down 15.22% on a QoQ basis from $46.0 million in Q4 2025.
Organon (OGN) Depreciation and Depletion (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Depreciation and Depletion for 7 consecutive years, with $39.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation and Depletion rose 14.71% year-over-year to $39.0 million; the TTM figure through Mar 2026 stood at $161.0 million (up 20.15% YoY), while the FY2025 annual figure was $156.0 million, up 18.18% from the prior year.
- Depreciation and Depletion came in at $39.0 million for Q1 2026 at Organon, down from $46.0 million in the prior quarter.
- The five-year high for Depreciation and Depletion was $46.0 million in Q4 2025, with the low at $22.0 million in Q2 2022.
- Average Depreciation and Depletion over 5 years is $31.9 million, with a median of $32.0 million recorded in 2023.
- The largest YoY upside for Depreciation and Depletion was 38.89% in 2022 against a maximum downside of 14.29% in 2022.
- Year by year, Depreciation and Depletion stood at $24.0 million in 2022, then surged by 33.33% to $32.0 million in 2023, then rose by 6.25% to $34.0 million in 2024, then jumped by 35.29% to $46.0 million in 2025, then retreated by 15.22% to $39.0 million in 2026.
- According to Business Quant data, Depreciation and Depletion over the past three periods registered $39.0 million, $46.0 million, and $40.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 188.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 39.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.00 Mn |
| Mar 31, 2026 | 39.00 Mn |
| Dec 31, 2025 | 46.00 Mn |
| Dec 31, 2025 | 46.00 Mn |
| Sep 30, 2025 | 40.00 Mn |
| Sep 30, 2025 | 40.00 Mn |
| Jun 30, 2025 | 36.00 Mn |
| Jun 30, 2025 | 36.00 Mn |
| Mar 31, 2025 | 34.00 Mn |
| Mar 31, 2025 | 34.00 Mn |
| Dec 31, 2024 | 34.00 Mn |
| Dec 31, 2024 | 34.00 Mn |
| Sep 30, 2024 | 34.00 Mn |
| Sep 30, 2024 | 34.00 Mn |
| Jun 30, 2024 | 32.00 Mn |
| Jun 30, 2024 | 32.00 Mn |
| Mar 31, 2024 | 32.00 Mn |
| Mar 31, 2024 | 32.00 Mn |
| Dec 31, 2023 | 32.00 Mn |
| Dec 31, 2023 | 32.00 Mn |